March 2019 //
Taliaz and Psychiatry UK Launch New Online Service to Provide Innovative Artificial Intelligence-Genetic Testing to Depression Sufferers.
Online medically-managed Predictix genetic testing service aims to reduce patient suffering by helping psychiatrists personalize antidepressant medication sooner.
“With depression the world’s number 1 health burden according to the World Health Organization, the online PREDICTIX service empowers psychiatrists to better tackle the often long and painful trial and error process that today’s patients face to find the right antidepressant,” said Dr. Dekel Taliaz, Taliaz CEO. “By using deep-data analysis, our PREDICTIX AI algorithm, understands the highly-complex role of each patients’ unique biological background and environment in driving behaviors, to personalize treatment.”
A recent study found that 65% of patients do not achieve remission following their first antidepressant treatment, and another 30% completely stop their ineffective treatment.
The service was fully launched at PUK’s Annual General Meeting that took place at the end of last month, following a successful pilot phase with great feedback:
“One of our patients who had not responded to four antidepressants, reported that after starting the medication recommended by the Predictix test three weeks previous, is now feeling like ‘I am a different person’ and ‘I feel 80% better in myself’,” said Dr Adil Jawad, Psychiatrist at Psychiatry UK, MBBS DPM FRCPsych.